ATOSSA THERAPEUTICS, INC. Impairment of Intangible Assets (Excluding Goodwill)
ATOSSA THERAPEUTICS, INC. (ATOS) reported Impairment of Intangible Assets (Excluding Goodwill) of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2020-03-26
- ATOSSA THERAPEUTICS, INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2019-12-31 was -$1.74M.
- ATOSSA THERAPEUTICS, INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- ATOSSA THERAPEUTICS, INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2019-06-30 was $0.00.
- ATOSSA THERAPEUTICS, INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2019-03-31 was $1.74M.
- ATOSSA THERAPEUTICS, INC. impairment of intangible assets (excluding goodwill) for fiscal 2019 was $0.00.
- ATOSSA THERAPEUTICS, INC. impairment of intangible assets (excluding goodwill) for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- ATOSSA THERAPEUTICS, INC. impairment of intangible assets (excluding goodwill) for fiscal 2017 was $461.71K, a 35.78% decline from fiscal 2016.
- ATOSSA THERAPEUTICS, INC. impairment of intangible assets (excluding goodwill) for fiscal 2016 was $718.97K.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month | Impairment of Intangible Assets (Excluding Goodwill) 9 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | -$1.74M derived: sum of 2 quarters · filed 2020-03-26 | -$1.74M derived: sum of 3 quarters · filed 2020-03-26 | $0.00 10-K · filed 2020-03-26 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $0.00 derived: sum of 2 quarters · filed 2019-11-13 | $1.74M 10-Q · filed 2019-11-13 | -$438.74K derived: sum of 4 quarters · filed 2020-03-26 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $1.74M 10-Q · filed 2019-08-13 | -$438.74K derived: sum of 3 quarters · filed 2020-03-26 | $184.76K derived: sum of 4 quarters · filed 2020-03-26 |
| 2019-03-31 | $1.74M 10-Q · filed 2019-05-13 | -$438.74K derived: sum of 2 quarters · filed 2020-03-26 | $184.76K derived: sum of 3 quarters · filed 2020-03-26 | |
| 2018-12-31 | -$2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | -$1.56M derived: sum of 2 quarters · filed 2020-03-26 | $0.00 10-K · filed 2020-03-26 | |
| 2018-09-30 | $623.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $2.18M 10-Q · filed 2019-11-13 | ||
| 2018-06-30 | $1.56M 10-Q · filed 2019-08-13 | |||
| 2017-12-31 | $461.71K 10-K · filed 2019-03-28 | |||
| 2016-12-31 | $718.97K 10-K · filed 2018-03-08 | |||
| 2015-12-31 | $0.00 10-K · filed 2016-03-30 | |||
| 2014-12-31 | $2.35M 10-K · filed 2016-03-30 | |||
| 2013-12-31 | $0.00 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |